Skip to main content

Advertisement

SpringerLink
Log in

Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials

  • Palliative and Supportive Care (MP Davis, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The importance of assessing health-related quality of life (HRQoL) and patient-reported outcomes (PROs) is now well recognized as an essential measure when evaluating the effectiveness of new cancer therapies. Quality of life measures provide for a multi-dimensional understanding of the impact of cancer treatment on measures ranging from functional, psychological, and social aspects of a patient’s health. Patient-reported outcomes provide for an assessment of physical and functional symptoms that are directly elicited from patients. Collection of PROs and HRQoL data has been shown to not only be feasible but also provide for reliable measures that correlate with established outcome measures better than clinician-scored toxicities. The importance of HRQoL measures has been emphasized by both patients and clinicians, as well as policy makers and regulatory bodies. Given the benefits associated with measuring HRQoL and PROs in oncology clinical trials, it is increasingly important to establish methods to effectively incorporate PROs and HRQoL measures into routine clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

    Article  PubMed  Google Scholar 

  2. Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer. 1999;83:132–7. https://doi.org/10.1002/(sici)1097-0215(1999)83:12+<132::aid-ijc23>3.0.co;2-4.

    Article  Google Scholar 

  3. Minasian LM, O’Mara AM, Reeve BB, et al. Health-related quality of life and symptom management research sponsored by the national cancer institute. In: Journal of Clinical Oncology. ; 2007. https://doi.org/10.1200/JCO.2007.12.6672, .

  4. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology: In; 2007. https://doi.org/10.1200/JCO.2007.11.3183.

    Book  Google Scholar 

  5. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25:535–52. https://doi.org/10.1016/j.cct.2004.09.003.

    Article  PubMed  Google Scholar 

  6. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA - J Am Med Assoc. 2012:1583–4. https://doi.org/10.1001/jama.2012.500.

  7. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–55. https://doi.org/10.1200/JCO.2012.42.5967.

    Article  PubMed  Google Scholar 

  8. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. J Oncol Pract. 2012;8(12):142–8. https://doi.org/10.1200/jop.2011.000525.

    Article  Google Scholar 

  9. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. J Am Med Assoc. 2002;288(23):3027–34. https://doi.org/10.1001/jama.288.23.3027.

    Article  Google Scholar 

  10. Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018;127:431–9. https://doi.org/10.1016/j.radonc.2018.05.016.

    Article  PubMed  Google Scholar 

  11. Gilbert A, Ziegler L, Martland M, Davidson S, Efficace F, Sebag-Montefiore D, et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. Int J Radiat Oncol Biol Phys. 2015;92:555–67. https://doi.org/10.1016/j.ijrobp.2015.02.021.

    Article  PubMed  Google Scholar 

  12. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22:3485–90. https://doi.org/10.1200/JCO.2004.03.025.

    Article  PubMed  Google Scholar 

  13. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159–64. https://doi.org/10.1007/s11136-011-0031-4.

    Article  PubMed  Google Scholar 

  14. Flynn KE, Jeffery DD, Keefe FJ, Porter LS, Shelby RA, Fawzy MR, et al. Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). Psychooncology. 2011;20:378–86. https://doi.org/10.1002/pon.1738.

    Article  PubMed  Google Scholar 

  15. Kotronoulas G, Kearney N, Maguire R, Harrow A, di Domenico D, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32:1480–501. https://doi.org/10.1200/JCO.2013.53.5948.

    Article  PubMed  Google Scholar 

  16. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557–65. https://doi.org/10.1200/JCO.2015.63.0830.

    Article  CAS  PubMed  Google Scholar 

  17. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73:177–83. https://doi.org/10.1006/gyno.1999.5387.

    Article  CAS  PubMed  Google Scholar 

  18. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76. https://doi.org/10.1016/j.ijrobp.2005.10.019.

    Article  PubMed  Google Scholar 

  19. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13. https://doi.org/10.1200/JCO.2000.18.8.1606.

    Article  CAS  PubMed  Google Scholar 

  20. Scholten AN, Van Putten WLJ, Beerman H, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–8. https://doi.org/10.1016/j.ijrobp.2005.03.007.

    Article  PubMed  Google Scholar 

  21. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:744–51. https://doi.org/10.1016/j.ygyno.2003.11.048.

    Article  PubMed  Google Scholar 

  22. Wortman BG, Creutzberg CL, Putter H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018;119:1067–74. https://doi.org/10.1038/s41416-018-0310-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Monk BJ, Huang HQ, Cella D, Long HJ, Mackey D. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23(21):4617–25. https://doi.org/10.1200/JCO.2005.10.522.

    Article  CAS  PubMed  Google Scholar 

  24. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113–9. https://doi.org/10.1200/JCO.2004.04.170.

    Article  CAS  PubMed  Google Scholar 

  25. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(11):2159–66. https://doi.org/10.1200/JCO.2004.07.184.

    Article  CAS  PubMed  Google Scholar 

  26. Creutzberg CL, Van Putten WLJ, Koper PCM, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11. https://doi.org/10.1016/S0140-6736(00)02139-5.

    Article  CAS  PubMed  Google Scholar 

  27. Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol. 2018;36(24):2538–44. https://doi.org/10.1200/JCO.2017.77.4273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, et al. Health-related quality of life in locally advanced cervical cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2016;94:1088–98. https://doi.org/10.1016/j.ijrobp.2015.12.363.

    Article  PubMed  Google Scholar 

  29. Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018;127:423–30. https://doi.org/10.1016/j.radonc.2018.05.002.

    Article  PubMed  Google Scholar 

  30. Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the embrace study. Int J Radiat Oncol Biol Phys. 2014;89:88–95. https://doi.org/10.1016/j.ijrobp.2014.01.032.

    Article  PubMed  Google Scholar 

  31. D. NJ, S. S, N. BKJ, et al. Physician assessed and patient reported limb edema after RCHT + IGABT for cervical cancer (EMBRACE). Radiother Oncol. 2017.

  32. Campbell BH, Marbella A, Layde PM. Quality of life and recurrence concern in survivors of head and neck cancer. Laryngoscope. 2000;110:895–906. https://doi.org/10.1097/00005537-200006000-00003.

    Article  CAS  PubMed  Google Scholar 

  33. Ringash J. Survivorship and quality of life in head and neck cancer. J Clin Oncol. 2015;33(29):3322–7. https://doi.org/10.1200/JCO.2015.61.4115.

    Article  PubMed  Google Scholar 

  34. Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37:1578–89. https://doi.org/10.1200/JCO.19.00441.

    Article  PubMed  Google Scholar 

  35. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40–50. https://doi.org/10.1016/S0140-6736(18)32779-X.

    Article  CAS  PubMed  Google Scholar 

  36. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51–60. https://doi.org/10.1016/S0140-6736(18)32752-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20:P1349–59. https://doi.org/10.1016/S1470-2045(19)30410-3.

    Article  Google Scholar 

  38. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36. https://doi.org/10.1016/S1470-2045(10)70290-4.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Rathod S, Gupta T, Ghosh-Laskar S, Murthy V, Budrukkar A, Agarwal J. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized s. Oral Oncol. 2013;49:634–42. https://doi.org/10.1016/j.oraloncology.2013.02.013.

    Article  PubMed  Google Scholar 

  40. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37. https://doi.org/10.1056/NEJMoa1606221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;98(3):581–9. https://doi.org/10.1016/j.ijrobp.2017.02.027.

    Article  PubMed  Google Scholar 

  42. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286–95. https://doi.org/10.1016/j.ijrobp.2017.01.008.

    Article  PubMed  Google Scholar 

  43. Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16:1605–16. https://doi.org/10.1016/S1470-2045(15)00280-6.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Shaikh T, Li T, Handorf EA, Johnson ME, Wang LS, Hallman MA, et al. Long-term patient-reported outcomes from a phase 3 randomized prospective trial of conventional versus Hypofractionated radiation therapy for localized prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;97:722–31. https://doi.org/10.1016/j.ijrobp.2016.12.034.

    Article  PubMed  Google Scholar 

  45. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, et al. Patient-reported urinary, bowel, and sexual function after Hypofractionated intensity-modulated radiation therapy for prostate Cancer. Am J Clin Oncol Cancer Clin Trials. 2018;41:558–67. https://doi.org/10.1097/COC.0000000000000325.

    Article  Google Scholar 

  46. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial. JAMA - J Am Med Assoc. 2016;316:401–9. https://doi.org/10.1001/jama.2016.9839.

    Article  Google Scholar 

  47. Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EHJM, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer. 1998;34:1902–9. https://doi.org/10.1016/S0959-8049(98)00268-8.

    Article  CAS  PubMed  Google Scholar 

  48. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority. Lancet. 2016;388:2004–14. https://doi.org/10.1016/S0140-6736(16)30825-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised standardisation of breast radiotherapy (START) trials. Lancet Oncol. 2010;11:231–40. https://doi.org/10.1016/S1470-2045(09)70382-1.

    Article  PubMed  Google Scholar 

  50. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–60. https://doi.org/10.1016/S0140-6736(17)31145-5.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bhattacharya IS, Haviland JS, Kirby AM, Kirwan CC, Hopwood P, Yarnold JR, et al. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the import low (CRUK/ 06/003) phase III randomized controlled trial. J Clin Oncol. 2019;37(4):305–17. https://doi.org/10.1200/JCO.18.00982.

    Article  CAS  PubMed  Google Scholar 

  52. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22:1161–75. https://doi.org/10.1007/s11136-012-0252-1.

    Article  PubMed  Google Scholar 

  53. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA - J Am Med Assoc. 2013;309:814–22. https://doi.org/10.1001/jama.2013.879.

    Article  CAS  Google Scholar 

  54. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The patient-reported outcomes measurement information system (PROMIS): Progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;5:S3–11. https://doi.org/10.1097/01.mlr.0000258615.42478.55.

    Article  Google Scholar 

  55. Snyder CF, Jensen RE, Segal JB, Wu AW. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care. 2013;51:S73–9. https://doi.org/10.1097/MLR.0b013e31829b1d84.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of Cancer therapy - breast (FACT-B) to the 5-level EuroQoL group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12:180. https://doi.org/10.1186/s12955-014-0180-6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist. 2014;19(2):127–34. https://doi.org/10.1634/theoncologist.2013-0359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Mohamed AF, Hauber AB, Johnson FR, Coon CD. Patient preferences and linear scoring rules for patient-reported outcomes. Patient. 2010;3:217–27. https://doi.org/10.2165/11537880-000000000-00000.

    Article  PubMed  Google Scholar 

  59. Tinelli M, Ozolins M, Bath-Hextall F, Williams HC. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol. 2012;12(1):19. https://doi.org/10.1186/1471-5945-12-19.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142:101–7. https://doi.org/10.1007/s10549-013-2727-3.

    Article  CAS  PubMed  Google Scholar 

  61. Hodgkins P, Lloyd A, Erder MH, Setyawan J, Weiss MD, Sasané R, et al. Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectr. 2017;22(1):31–40. https://doi.org/10.1017/S1092852916000353.

    Article  PubMed  Google Scholar 

  62. Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, et al. Important group differences on the functional assessment of cancer therapy–kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma. Value Heal. 2018;21(12):1413–8. https://doi.org/10.1016/j.jval.2018.04.1371.

    Article  Google Scholar 

  63. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37(5):469–78. https://doi.org/10.1097/00005650-199905000-00006.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA

    Jill S. Remick MD, Emily Kowalski MD, Santanu Samanta MD & Mark V. Mishra MD

  2. University of Maryland School of Medicine, Baltimore, MD, USA

    Sung Choi BS

  3. Department of Radiation Oncology, The Ohio State University, Columbus, OH, USA

    Joshua D. Palmer MD

  4. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA

    Mark V. Mishra MD

Authors
  1. Jill S. Remick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily Kowalski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santanu Samanta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sung Choi BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joshua D. Palmer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark V. Mishra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark V. Mishra MD.

Ethics declarations

Conflict of interest

MM reports honorarium from Varian Medical Systems, unrelated to the scope of the current work. JP reports a grant from Varian Medical Systems, as well as consulting and speaker fees from Huron Consulting and DePuy Synthes.

Jill S. Remick declares that she has no conflict of interest. Emily Kowalski declares that she has no conflict of interest. Santanu Samtana declares that he has no conflict of interest. Sung Choi declares that he has no conflict of interest. Joshua D. Palmer has received research funding from Varian Medical Systems, and has received compensation from DePuy Synthes and Huron Consulting Group for service as a consultant and a guest speaker. Mark V. Mishra has received honoraria and reimbursement for travel expenses from Varian Medical Systems.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Palliative and Supportive Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Remick, J.S., Kowalski, E., Samanta, S. et al. Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials. Curr. Treat. Options in Oncol. 21, 87 (2020). https://doi.org/10.1007/s11864-020-00782-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00782-4

Keywords

Search

Navigation